文献速递哮喘

tezepelumab助力重度激素依赖性哮喘减少或停用口服激素:WAYFINDER 3b期研究

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial.
PubMed 文献 · Lancet Respir Med · 2025-11-26

WAYFINDER为多中心、单臂、开放标签3b期研究,纳入298例接受维持口服激素(OCS)5–40 mg/日、重度未控制哮喘成人,予tezepelumab 210 mg皮下注射每4周一次至52周。

要点

  • OCS减停效果在基线血嗜酸性粒细胞、FeNO及过敏状态各亚组中均可见

核心结论

  • 开放标签tezepelumab治疗52周后,近90%的OCS依赖性重度未控制哮喘患者维持OCS≤5 mg/日,超过50%完全停用OCS且维持哮喘控制。
  • 作者认为tezepelumab可帮助重度哮喘患者减少OCS使用及其相关负担,且在不同表型患者中广泛适用。

研究设计与样本

  • 3b期、多中心、单臂、开放标签、OCS减量研究,研究于2022年5月17日至2024年9月9日开展。
  • 自11个国家68个中心招募18–80岁重度未控制哮喘成人,基线维持OCS为泼尼松或泼尼松龙5–40 mg/日(或等效剂量)。
  • 共同主要终点为第28周和第52周将维持OCS减至≤5 mg/日且未失去哮喘控制的比例,以及停用OCS且未失去哮喘控制的比例。
  • OCS减至5 mg/日以下需以肾上腺功能保留为前提,研究注册号NCT05274815。

主要发现

  • OCS减量与停用在按基线血嗜酸性粒细胞计数、呼出气一氧化氮水平或过敏状态划分的预设亚组中均可实现。

关键数值与推荐

  • 共同主要终点评估时点为第28周和第52周。
  • OCS减至5 mg/日以下需以肾上腺功能保留为前提。

临床怎么用

  • 对OCS依赖性重度未控制哮喘成人,可考虑tezepelumab 210 mg皮下注射每4周一次以协助减少OCS用量。
  • 减停OCS过程中需以哮喘控制未丧失为条件,减至5 mg/日以下前需确认肾上腺功能保留。
  • 疗效在基线血嗜酸性粒细胞、FeNO及过敏状态不同亚组中均可出现,选择患者时不必仅限特定表型。

局限性

  • 研究为单臂、开放标签设计,无安慰剂对照,结果解释需谨慎。
  • 入组382例中298例接受治疗并纳入分析,样本量与随访至52周。
  • 研究未设对照组,无法直接比较tezepelumab与其他治疗的减停效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SOURCE phase 3 oral corticosteroid (OCS)-sparing study of tezepelumab indicated an OCS-sparing effect with tezepelumab versus placebo in patients with OCS-dependent asthma and baseline blood eosinophil counts (BECs) of at least 150 cells per μL. The WAYFINDER study aimed to further evaluate the ability of tezepelumab to reduce or discontinue OCS use in a larger cohort of patients with OCS-dependent severe, uncontrolled asthma. METHODS: WAYFINDER was a phase 3b, multicentre, single-arm, open-label, OCS-sparing study. Adults (aged 18-80 years) with severe, uncontrolled asthma receiving a maintenance OCS dose of 5-40 mg per day (or equivalent) of prednisone or prednisolone were recruited from 68 clinical centres across 11 countries (Argentina, Belgium, Bulgaria, France, Germany, Latvia, Mexico, Poland, Spain, UK, and USA). Participants received tezepelumab 210 mg subcutaneously once every 4 weeks for up to 52 weeks. The co-primary endpoints, assessed at weeks 28 and 52, were the proportion of participants who reduced their prescribed maintenance OCS dose to 5 mg per day or less without loss of asthma control and the proportion of participants who discontinued OCS without loss of asthma control. OCS dose reductions to below 5 mg per day were contingent on participants demonstrating preserved adrenal function. This completed study was registered with ClinicalTrials.gov (NCT05274815). FINDINGS: WAYFINDER was conducted between May 17, 2022, and Sept 9, 2024. Overall, 382 participants were enrolled and 298 participants (206 female [69·1%]) received tezepelumab and were included in the efficacy and safety analyses. The mean baseline maintenance OCS dose was 10·8 (SD 6·5) mg per day. The proportion of participants who had a maintenance OCS dose of 5 mg per day or less without loss of asthma control was 265 of 298 (88·9% [95% CI 84·8-92·3]) at week 28 and 268 of 298 (89·9% [85·9-93·1]) at week 52. The proportion of participants who discontinued OCS without loss of asthma control was 96 of 298 (32·2% [26·9-37·8]) at week 28 and 150 of 298 (50·3% [44·5-56·2]) at week 52. OCS reduction and discontinuation were achieved across pre-specified subgroups based on baseline BEC, fractional exhaled nitric oxide level, or allergy status. Serious adverse events were reported in 28 (9·4%) of 298 participants (asthma [13 participants] and pneumonia [three participants] were the most common), and four participants (1·3%) had adverse events leading to tezepelumab discontinuation. Two participants died during the study but neither death was considered to be causally related to tezepelumab treatment. INTERPRETATION: After 52 weeks of open-label tezepelumab treatment, nearly 90% of patients with OCS-dependent severe, uncontrolled asthma had a maintenance OCS dose of 5 mg per day or less and more than 50% completely discontinued OCS, while maintaining asthma control. These findings indicate that tezepelumab treatment can help enable patients with severe asthma to reduce their OCS use and its associated burden, with broad applicability across patient phenotypes. FUNDING: AstraZeneca and Amgen.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Jackson DJ, Lugogo NL, Gurnell M, et al. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir Med. 2025. PMID: 41317738. doi:10.1016/S2213-2600(25)00359-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。